– USA, TX – SWK Holdings Corporation (Nasdaq: SWKH), a life-science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced the appointment of Jerry Albright to its Board of Directors effective March 15, 2023, replacing Wendy DiCicco who chose not to seek re-election to the Board.
About Jerry Albright
Mr. Albright is currently a managing partner of ADIM, LLC, an investment management firm specializing in establishing protocols, policies, and practices for boards of directors. Prior to ADIM, Mr. Albright held multiple roles of increasing responsibility at the Teacher Retirement System of Texas for nearly three decades until his retirement in May 2020, including as TRS Investment Division’s Deputy CIO, COO, Director of Investment Operations and, most recently, as CIO, in which capacity he served from mid-2017 until his retirement. Prior to joining TRS, Mr. Albright was EVP and a member of the board of directors of a multi-bank holding company in Texas, in addition to serving as a director on the board of two affiliated banks. Mr. Albright has also previously served on the Advisory Board of the Finance Department at Texas A&M University.
Mr. Albright holds a bachelor’s degree in economics from Texas A&M University.
About SWK Holdings Corporation
SWK Holdings Corporation is a life science-focused specialty finance company partnering with small- and mid-sized commercial-stage healthcare companies. SWK provides non-dilutive financing to fuel the development and commercialization of lifesaving and life-enhancing medical technologies and products. SWK’s unique financing structures provide flexible financing solutions at an attractive cost of capital to create long-term value for all SWK stakeholders. SWK’s solutions include structured debt, traditional royalty monetization, synthetic royalty transactions, and asset purchases typically ranging in size from $5.0 million to $25.0 million. SWK also owns Enteris BioPharma, whose Peptelligence and ProPerma drug delivery technologies create oral formulations of peptide-based and BCS class II, III, and IV small molecules.
For more information: https://www.swkhold.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.